24/7 Market News Snapshot 31 October, 2024 – Autonomix Medical, Inc. Common Stock (NASDAQ:AMIX)

October 31, 2024

DENVER, Colo., 31 October, 2024 (247marketnews.com) – (NASDAQ:AMIX) are discussed in this article.
Autonomix Medical, Inc. (NASDAQ:AMIX) is experiencing significant market momentum with a remarkable 50.13% surge in pre-market trading, bringing shares to $15.373 from a previous close of $10.240. This impressive increase is underscored by a substantial trading volume of 1.09 million shares, reflecting heightened investor interest and confidence in the company’s strategic direction.

Simultaneously, Autonomix also reported promising early results from its ongoing proof-of-concept clinical trial designed to provide innovative pain management solutions for pancreatic cancer patients. With 60% enrollment achieved and 15 participants successfully treated, the preliminary data indicates a notable 79% responder rate, coupled with a mean pain reduction of 4.96 points on the Visual Analog Scale (VAS), representing a 63% decrease in pain within just seven days post-procedure. Importantly, these results highlight a complete absence of opioid reliance among participants, showcasing the potential for a transformative approach in managing pain while mitigating the risks associated with opioid therapies.

CEO Brad Hauser conveyed enthusiasm regarding the trial’s outcomes, emphasizing the revolutionary potential for treating pain without resorting to opioids. Chief Medical Officer Dr. Robert Schwartz echoed these sentiments, pointing to the high prevalence of pain in pancreatic cancer patients and the current limitations of treatment options as motivators for advancing their technology.

The trial leverages Autonomix’s state-of-the-art microchip sensing capabilities, which enable precise identification and targeting of problematic nerves. As enrollment progresses, Autonomix is committed to further developing this pioneering treatment strategy, offering hope for improved quality of life for those affected by pancreatic cancer and similar conditions. Strong market performance combined with these promising clinical developments positions Autonomix at the forefront of both medical innovation and investment interest, emphasizing its potential impact on the healthcare landscape.

Related news for (AMIX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.